Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials
- PMID: 18032899
- DOI: 10.1159/000109358
Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials
Abstract
Background: Because many dermatological diseases are chronic but not life-threatening, consideration of their impact on health-related quality of life (QOL) seems essential.
Objective: To analyze the use of QOL as an evaluation endpoint in randomized clinical trials concerning skin diseases.
Methods: Studies identified by computerized search of 3 bibliographical databases were selected, and their data on QOL as an evaluation endpoint were collected and analyzed.
Results: Among the 67 studies retained, 87% did not adequately describe the questionnaires; 75% did not address handling of missing data; 95% did not calculate the number of subjects needed to obtain the desired statistical power; 95% did not disclose before-and-after results as means of overall scores and each dimension.
Conclusion: Our analysis highlighted methodological weaknesses in the use of QOL questionnaire and poor reporting of QOL outcomes in randomized clinical trials.
(c) 2008 S. Karger AG, Basel
Similar articles
-
Outcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years?J Dermatolog Treat. 2007;18(5):261-7. doi: 10.1080/09546630701487635. J Dermatolog Treat. 2007. PMID: 17917937 Review.
-
Analyzing the "correct" endpoint.Curr Probl Cancer. 2006 Nov-Dec;30(6):283-97. doi: 10.1016/j.currproblcancer.2006.08.006. Curr Probl Cancer. 2006. PMID: 17123880
-
Feasibility of modified DLQI-based questionnaires for evaluation of clinical efficacy of herbal medicine in chronic skin diseases.Tokai J Exp Clin Med. 2005 Jul;30(2):97-102. Tokai J Exp Clin Med. 2005. PMID: 16146199
-
Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology.J Clin Epidemiol. 2006 Dec;59(12):1257-65. doi: 10.1016/j.jclinepi.2006.03.006. Epub 2006 Jul 3. J Clin Epidemiol. 2006. PMID: 17098568 Review.
-
Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.Pain Physician. 2009 Sep-Oct;12(5):819-50. Pain Physician. 2009. PMID: 19787009
Cited by
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2021 Apr 19;4:CD011535. doi: 10.1002/14651858.CD011535.pub4. PMID: 31917873 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2023 Jul 12;7:CD011535. doi: 10.1002/14651858.CD011535.pub6. PMID: 35603936 Free PMC article. Updated.
-
Declaration of transparency for each research article.BMJ. 2013 Aug 7;347:f4796. doi: 10.1136/bmj.f4796. BMJ. 2013. PMID: 23924655 Free PMC article.
-
Application of the dermatology life quality index in clinical trials of biologics for psoriasis.Chin J Integr Med. 2012 Mar;18(3):179-85. doi: 10.1007/s11655-012-1007-0. Epub 2012 Apr 2. Chin J Integr Med. 2012. PMID: 22466941 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
